Αποτελέσματα Αναζήτησης
25 Ιαν 2023 · This vaccine effectiveness indicates the additional benefit of receiving a single booster dose rather than the effectiveness as compared with being unvaccinated. The results are shown in...
11 Μαΐ 2023 · Herein, we report long-term efficacy and safety of axi-cel in patients with refractory LBCL from phase 2 of ZUMA-1 after 5 years of follow-up, including exploratory analyses to assess durability of response and long-term survival.
13 Απρ 2023 · Our results show that the vaccine effectiveness (calculated as 100 × [1–HR]) of a bivalent BA.4 and BA.5 mRNA vaccine booster dose among eligible adults aged 65 years or older is 72% (95% CI 60–81) for hospitalisation due to COVID-19 and 68% (95% CI 42–82) for death due to COVID-19.
25 Ιαν 2023 · effectiveness against severe infection resulting in hospitalization over days 15 to 99 after receipt of one monovalent booster dose was 25.2% (95% confidence interval [CI], –0.2 to 44.2), and...
16 Σεπ 2022 · Results. Interim results are presented. Sequential groups of participants received 50 μg of mRNA-1273.214 (437 participants) or mRNA-1273 (377 participants) as a second booster dose. The...
27 Οκτ 2023 · The results show that a second vaccine booster effectively prevents COVID-19-related ICU admission and death and provides additional protection compared to the first booster.
30 Μαΐ 2017 · ZUMA-1 is the first, multicenter trial of anti-CD19 chimeric antigen receptor (CAR) T cells, axi-cel, in r-NHL. Methods: Dosing and eligibility were per Neelapu ASH 2016. The primary endpoint was objective response rate (ORR); secondary endpoints were duration of response (DOR), overall survival (OS), and safety.
